Growth factors for early decompensated cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This study tests whether a combination of two medicines (G-CSF and darbepoetin) given in one or more cycles can improve the body's immune and metabolic health in people with early-stage decompensated cirrhosis (advanced liver disease with mild complications). It compares these treatments with standard medical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have cirrhosis that has caused ascites (fluid buildup in the belly), but it is not severe or complicated
- You have not had alcohol in the last 3 months
- You have not had bleeding from your esophagus in the last 6 weeks
- You have not had confusion or coma due to liver disease in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether stem cells from umbilical cord blood can safely help people with advanced liver scarring (cirrhosis) caused by hepatitis B. It may offer a new option for those who haven't improved with usual treatments.
This trial tests whether giving a medicine that helps the body make more blood cells (called GCSF and darbepoetin) either once or a few times can help people with early liver failure (decompensated cirrhosis). The goal is to see if it helps the liver work better and improve the patient's health.
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
This trial tests a new cell injection called HCL001 for people with decompensated cirrhosis (advanced liver scarring causing complications). The goal is to see if it's safe and helps improve liver function. It may be an option if you've tried standard treatments and meet specific health criteria.
This trial tests an experimental liver cell injection to see if it is safe and can help people with decompensated cirrhosis, a serious liver condition. If you qualify, you may receive this new treatment to potentially improve liver function.
Hear when a new Decompensated Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.